Brief: Ab&B Bio Tech Enters Strategic Cooperation Agreement With Walvax Hong Kong
13/03/2026 11:00
March 13 (Reuters) - Ab&B Bio Tech Co Ltd JS 2627.HK: ENTERS STRATEGIC COOPERATION AGREEMENT WITH WALVAX HONG KONG LTD CORE PRODUCT FOR EXPANSION IS TRIVALENT SUBUNIT INFLUENZA VACCINE HUIERKANGXIN 3 Further company coverage: 2627.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ab&B Bio Tech Co JS
See all newsBrief: Ab&B Bio Tech Enters Strategic Cooperation Agreement With Walvax Hong Kong
Ab&B Bio Tech hits record high on inclusion in Hang Seng Composite Index
Brief: AB&B Bio Tech Co Ltd JS Says H Shares Included In Hang Seng Composite Index Effective March 9
Ab&B gains as human rabies vaccine commences Phase III clinical trials
Brief: Ab&B Bio Tech Co Ltd JS Announces Approval For Quadrivalent Subunit Influenza Vaccine By China's NMPA